BDF Gestion Acquires New Shares in Moderna, Inc. (NASDAQ:MRNA)

BDF Gestion purchased a new position in Moderna, Inc. (NASDAQ:MRNA - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 27,611 shares of the company's stock, valued at approximately $783,000.

A number of other hedge funds also recently bought and sold shares of the business. Empowered Funds LLC raised its holdings in shares of Moderna by 11.2% during the fourth quarter. Empowered Funds LLC now owns 5,781 shares of the company's stock valued at $240,000 after acquiring an additional 582 shares during the last quarter. Asset Management One Co. Ltd. increased its position in Moderna by 1.1% during the fourth quarter. Asset Management One Co. Ltd. now owns 123,051 shares of the company's stock worth $4,938,000 after purchasing an additional 1,381 shares during the last quarter. V Square Quantitative Management LLC raised its stake in Moderna by 38.0% during the fourth quarter. V Square Quantitative Management LLC now owns 7,797 shares of the company's stock worth $324,000 after purchasing an additional 2,148 shares during the period. AustralianSuper Pty Ltd boosted its holdings in Moderna by 14.3% in the 4th quarter. AustralianSuper Pty Ltd now owns 16,584 shares of the company's stock valued at $690,000 after purchasing an additional 2,077 shares during the last quarter. Finally, Blue Trust Inc. raised its position in shares of Moderna by 140.1% during the 4th quarter. Blue Trust Inc. now owns 1,755 shares of the company's stock valued at $73,000 after buying an additional 1,024 shares during the period. Hedge funds and other institutional investors own 75.33% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on MRNA shares. Citigroup began coverage on Moderna in a report on Thursday, March 13th. They set a "neutral" rating and a $40.00 price target for the company. Royal Bank Of Canada dropped their price target on shares of Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a research report on Friday, May 2nd. Morgan Stanley decreased their price objective on shares of Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a report on Wednesday, April 9th. JPMorgan Chase & Co. cut their target price on Moderna from $33.00 to $26.00 and set an "underweight" rating on the stock in a research report on Thursday, May 22nd. Finally, William Blair reaffirmed a "market perform" rating on shares of Moderna in a research note on Monday, June 2nd. Four analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $46.61.

Moderna Stock Down 0.6%

Shares of MRNA traded down $0.15 during midday trading on Thursday, hitting $25.40. The company had a trading volume of 7,517,553 shares, compared to its average volume of 8,450,893. The stock has a market cap of $9.82 billion, a price-to-earnings ratio of -2.91 and a beta of 1.86. The company's 50 day moving average price is $26.27 and its 200 day moving average price is $32.69. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $138.07.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, beating the consensus estimate of ($2.92) by $0.40. The company had revenue of $108.00 million for the quarter, compared to analyst estimates of $130.35 million. Moderna had a negative net margin of 105.67% and a negative return on equity of 28.69%. Moderna's revenue was down 35.3% compared to the same quarter last year. During the same quarter last year, the business earned ($3.07) earnings per share. Equities analysts anticipate that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.